Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center

Psychiatric Services

Volumn 54, Issue 2, 2003, Pages 195-200

  Dobscha, Steven K ^a   Anderson, Thomas A ^a   Hoffman, William F ^a   Winterbottom, Lisa M ^a   Turner, Erick H ^a   Snodgrass, Leann S ^a   Hauser, Peter ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; COMPUTER SYSTEM; CONTINUING EDUCATION; COST MINIMIZATION ANALYSIS; DEPRESSION; DRUG CHOICE; DRUG COST; DRUG IDENTIFICATION; DRUG UTILIZATION; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MEDICAL RECORD; MENTAL HEALTH SERVICE; NORMAL HUMAN; OUTPATIENT CARE; PATIENT EDUCATION; PHARMACY; PRESCRIPTION; PUBLIC HOSPITAL; SOLDIER; SYSTEM ANALYSIS; TABLET; TECHNIQUE; COMPARATIVE STUDY; COST CONTROL; DRUG ADMINISTRATION; ECONOMICS; HOSPITAL COST; MENTAL DISEASE; METHODOLOGY; UNITED STATES;

CITALOPRAM; CLINICAL PHARMACY INFORMATION SYSTEMS; COST CONTROL; COST SAVINGS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG UTILIZATION; FLUOXETINE; FLUVOXAMINE; HOSPITAL COSTS; HOSPITALS, VETERANS; HUMANS; MENTAL DISORDERS; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; UNITED STATES;

EID: 0038321026     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.54.2.195     Document Type: Article

References (25)

1. McCombs JS, Nichol MB, Stimmel GL, et al: The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. Journal of Clinical Psychiatry 51:60-69, 1990
2. Simon G, Ormel J, VonKorff M, et al: Health care costs associated with depresive and anxiety disorders in primary care. American Journal of Psychiatry 152:352-357, 1995
3. Simon GE, VonKorff M, Barlow W: Health care costs of primary care patients with recognized depression. Archives of General Psychiatry 52:850-856, 1995
4. Unutzer J, Patrick DL, Simon G, et al: Depressive symptoms and the cost of health services in HMO patients aged 65 years and older: a 4-year prospective study. JAMA 277:1618-1623, 1997
5. Von Korff M, Katon W, Bush T, et al: Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression. Psychosomatic Medicine 60:143-149, 1998
6. Croghan TW: The controversy of increased spending for antidepressants. Health Affairs 20 (2):129-135, 2001
7. Latner AW: Top 200 drugs by retail sales in 2000. Drug Topics 6:18, 2001
8. Moller HJ: Pharmacotherapy of depressed patients: increasing the therapeutic arsenal with a new generation of antidepressive drugs [in German]. Fortschritte der Medizin 115:30-34, 36, 1997
9. Fairman KA, Teitelbaum F, Drevets WC, et al: Course of antidepressant treatment with tricyclic versus selective serotonin reuptake inhibitor agents: a comparison in managed care and fee-for-service environments. American Journal of Managed Care 3:453-465, 1997
10. Frank L, Revicki DA, Sorensen SV, et al: The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs 15:59-83, 2001
11. Dubois RW, Chawla AJ, Neslusan CA, et al: Explaining drug spending trends: does perception match reality? Health Affairs 19 (2):231-239, 2000
12. Levine S, Campen D, Millares M, et al: Kaiser Permanente's prescription drug benefit. Health Affairs 19(2):185-190, 2000
13. Benkert O, Szegedi A, Wetzel H: Minimum effective dose for antidepressants: an obligatory requirement for antidepressant drug evaluation? International Clinical Psychopharmacology 11:177-185, 1996
14. Vodoor M, Southwell YP, Grubin M, et al: The management of depression: the implications for managed care - roundtable discussion: part 3. Managed Care Interface (suppl B):26-32, 2000
15. Singletary T, North DS, Weiss M, et al: A cost-effective approach to the use of selective serotonin reuptake inhibitors in a Veterans Affairs Medical Center. American Journal of Managed Care 3:125-129, 1997
16. Cohen CI, Cohen SI: Potential cost savings from pill splitting of newer psychotropic medications. Psychiatric Services 51:527-529, 2000
17. Stafford RS, Radley DC: The potential of pill splitting to achieve cost savings. American Journal of Managed Care 8:706-712, 2002
18. Hankin CS, Spiro A III, Miller DR, et al: Mental disorders and mental health treatment among US Department of Veterans Affairs outpatients: the Veterans Health Study. American Journal of Psychiatry 156:1924-1930, 1999
19. Rosenheek R, Leslie D: Cost and Prescription of Antidepressant Medication in VA. New Haven, Conn, VA Northeast Program Evaluation Center and VISN 1 MIRECC, 2001
20. Streja DA, Hui RL, Streja E, et al: Selective contracting and patient outcomes: a case study of formular/restrictions for selective serotonin reuptake inhibitor antidepressants. American Journal of Managed Care 5:1133-1142, 1999
21. Geddes JR, Freemantle N, Mason J, et al: SSRIs versus other antidepressants for depressive disorder. Cochrane Database System Review: CD001851, 2000
22. Kazis LE, Miller DR, Clark J, et al: Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study. Archives of Internal Medicine 158:626-632, 1998
23. Mitchell J, Greenberg J, Finch K, et al: Effectiveness and economic impact of antidepressant medications: a review. American Journal of Managed Care 3:323-330, 1997
24. Saklad SR: Pharmacoeconomie issues in the treatment of depression. Pharmacotherapy 15 (suppl 6, pt 2):76S-83S, 1995
25. VHA Clinical Guideline for Major Depressive Disorder. Washington, DC, Veterans Health Administration, Mental Health and Strategic Health Care Group and MDD Working Group, 1998